Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Part of paid clinical trials in Orange, California.
- Sponsor
- Chugai Pharmaceutical
- Study ID
- NCT06371417
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Antiphospholipid Syndrome (APS)
- Behçet's Syndrome (BS)
- Bullous Pemphigoid (BP)
- Dermatomyositis (DM)
- Immune Thrombocytopenia (ITP)
- Immune-mediated Necrotizing Myopathy (IMNM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- RAY121 — DRUGInjection
Study Details
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Key Dates
- Start date
- Aug 19, 2024
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 144 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RAY121All enrolled patients will receive RAY121 multiple dose
Primary Outcome Measure
Adverse events (AEs) [ Time Frame: Baseline to Week 32 ]
Central Contacts
- Clinical trials informationonly use Email
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California-Irvine | Orange | California | 92868 | - |
| Johns Hopkins University | Baltimore | Maryland | 21224 | - |
| Northwell Health, LLC PRIME | Lake Success | New York | 11042 | - |
| Hospital for Special Surgery | New York | New York | 10021 | - |
| Universtity of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | - |
| Ohio State University | Columbus | Ohio | 43203 | - |
| Oregon Health & Science University | Portland | Oregon | 97239 | - |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | - |
| Amarillo Center for Clinical Research | Amarillo | Texas | 79124 | - |
| Austin Neuromuscular Center | Austin | Texas | 78759 | - |
| Nerve and Muscle Center of Texas | Houston | Texas | 77030 | - |
Find similar trials in Orange, CA
Related Studies
- A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaPHASE1/PHASE2 · Recruiting · Eli Lilly and Company · Los Angeles, California
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune ThrombocytopeniaPHASE2 · Recruiting · Nuvig Therapeutics, Inc. · Greenville, North Carolina
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)PHASE2 · Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Bethesda, Maryland